Press Releases

-
Jul 30, 2020ENGLEWOOD, CO / ACCESSWIRE / July 30, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on commercializing novel products that address significant patient needs, today announced the approval of ZolpiMist® (zolpidem tartrate oral spray) by the Therapeutic Goods Administration (TGA) in Australia. This approval, which was secured by the Company's ...Jul 27, 2020Article Reports Results from Independent Study Demonstrating Test's 100% Sensitivity and Specificity for IgM Antibodies and 96.7% and 97.5% Sensitivity and Specificity, Respectively, for IgG Antibodies...Jul 20, 2020Commercial Partner Acerus Pharmaceuticals Launches Specialty Sales Team Calling on Urologists and Endocrinologists in the United States ...Jul 10, 2020Apollo Med Innovations Introduces Novel Research-Based Testing Approach to Offer COVID-19 Antibody Testing to Nationwide Network of Over 1,000 Medical Clinics and Recently Launched Mobile Testing Platform...Jun 9, 2020National Cancer Institute's (NCI) analysis of COVID-19 IgG/IgM Rapid Test Cassette Reported 100% Combined Sensitivity, and 97.5% Combined Specificity for the Lateral Flow Immunoassay...Jun 8, 2020ENGLEWOOD, CO / ACCESSWIRE / June 8, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on commercializing novel products that address significant medical needs, is set to join the Russell 3000® Index at the conclusion of the 2020 Russell indexes annual reconstitution. The Russell index changes become effective after the close of the US markets ...Jun 3, 2020Natesto now covered as a Preferred Brand by leading national pharmacy benefits manager ...Jun 1, 2020Company Retires $15M Obligation Assumed with Previously Announced Cerecor Commercial Portfolio Asset Purchase...Jun 1, 2020Fourth FDA Emergency Use Authorization of a COVID-19 IgG/IgM Lateral Flow Rapid Test...May 14, 2020Company Reports Revenue for the Three Months Ended March 31, 2020 of $8.2M, Up 243% Year-over-Year...